Roy S. Herbst, deputy director of Yale Cancer Center and Smilow Cancer Hospital and assistant dean for translational research at Yale School of Medicine, was elected to the Friends of Cancer Research Board of Directors.
Tagrisso (osimertinib) plus chemotherapy delivers a statistically significant and clinically meaningful survival benefit compared to Tagrisso monotherapy in the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, according to results from the final overall survival analysis of the FLAURA2 phase III trial.
